Wai Yuen Tong Medicine Holdings Limited (0897.HK)
HKD 0.34
(0.0%)
HKD 0.34
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 40.88 Million HKD | -20.7% |
| 2022 | 51.55 Million HKD | -8.21% |
| 2021 | 56.16 Million HKD | 340.79% |
| 2020 | -23.32 Million HKD | 82.65% |
| 2019 | -134.43 Million HKD | 8.63% |
| 2018 | -147.13 Million HKD | -31.71% |
| 2017 | -111.71 Million HKD | 10.98% |
| 2016 | -125.5 Million HKD | -71.95% |
| 2015 | -72.98 Million HKD | -548.49% |
| 2014 | 16.27 Million HKD | -80.48% |
| 2013 | 83.37 Million HKD | -25.65% |
| 2012 | 112.13 Million HKD | 47.21% |
| 2011 | 76.17 Million HKD | 68.29% |
| 2010 | 45.26 Million HKD | 50.42% |
| 2009 | 30.09 Million HKD | 349.88% |
| 2008 | -12.04 Million HKD | -117.27% |
| 2007 | 69.73 Million HKD | 1016.05% |
| 2006 | -7.61 Million HKD | 84.17% |
| 2005 | -48.1 Million HKD | -16.91% |
| 2004 | -41.14 Million HKD | -47.63% |
| 2003 | -27.86 Million HKD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 Q2 | 66.13 Million HKD | 0.0% |
| 2023 FY | 40.88 Million HKD | -20.7% |
| 2023 Q4 | -24.08 Million HKD | 0.0% |
| 2022 Q2 | 6.76 Million HKD | 0.0% |
| 2022 FY | 51.55 Million HKD | -8.21% |
| 2022 Q4 | 44.78 Million HKD | 0.0% |
| 2021 Q4 | 27.98 Million HKD | 0.0% |
| 2021 FY | 56.16 Million HKD | 340.79% |
| 2021 Q2 | 32.04 Million HKD | 0.0% |
| 2020 Q4 | -5.12 Million HKD | 0.0% |
| 2020 Q2 | -17.97 Million HKD | 0.0% |
| 2020 FY | -23.32 Million HKD | 82.65% |
| 2019 FY | -134.43 Million HKD | 8.63% |
| 2019 Q4 | -57.68 Million HKD | 0.0% |
| 2019 Q2 | -68.46 Million HKD | 0.0% |
| 2018 FY | -147.13 Million HKD | -31.71% |
| 2018 Q4 | -65.98 Million HKD | 0.0% |
| 2018 Q2 | -81.15 Million HKD | 0.0% |
| 2017 Q2 | -54.71 Million HKD | 0.0% |
| 2017 Q4 | -57 Million HKD | 0.0% |
| 2017 FY | -111.71 Million HKD | 10.98% |
| 2016 Q4 | -70.72 Million HKD | 0.0% |
| 2016 Q2 | -54.77 Million HKD | 0.0% |
| 2016 FY | -125.5 Million HKD | -71.95% |
| 2015 Q2 | -44.3 Million HKD | 0.0% |
| 2015 Q4 | -28.68 Million HKD | 0.0% |
| 2015 FY | -72.98 Million HKD | -548.49% |
| 2014 Q2 | -30.52 Million HKD | -578.12% |
| 2014 FY | 16.27 Million HKD | -80.48% |
| 2014 Q3 | -13.96 Million HKD | 54.26% |
| 2014 Q4 | -13.96 Million HKD | 0.0% |
| 2014 Q1 | 6.38 Million HKD | 0.0% |
| 2013 FY | 83.37 Million HKD | -25.65% |
| 2013 Q4 | 6.38 Million HKD | 0.0% |
| 2013 Q3 | 6.38 Million HKD | -57.51% |
| 2013 Q2 | 15.02 Million HKD | 24.17% |
| 2013 Q1 | 12.1 Million HKD | 0.0% |
| 2012 Q1 | 19.04 Million HKD | 0.0% |
| 2012 Q2 | 19.04 Million HKD | 0.0% |
| 2012 Q3 | 12.1 Million HKD | -36.45% |
| 2012 Q4 | 12.1 Million HKD | 0.0% |
| 2012 FY | 112.13 Million HKD | 47.21% |
| 2011 Q1 | 11.31 Million HKD | 0.0% |
| 2011 FY | 76.17 Million HKD | 68.29% |
| 2011 Q4 | 19.04 Million HKD | 0.0% |
| 2011 Q3 | 19.04 Million HKD | 68.29% |
| 2011 Q2 | 11.31 Million HKD | 0.0% |
| 2010 Q4 | 11.31 Million HKD | 0.0% |
| 2010 FY | 45.26 Million HKD | 50.42% |
| 2010 Q1 | 7.58 Million HKD | 0.0% |
| 2010 Q2 | 7.58 Million HKD | 0.0% |
| 2010 Q3 | 11.31 Million HKD | 49.24% |
| 2009 Q1 | 1.09 Million HKD | 0.0% |
| 2009 Q2 | 1.09 Million HKD | 0.0% |
| 2009 Q3 | 7.58 Million HKD | 593.26% |
| 2009 FY | 30.09 Million HKD | 349.88% |
| 2009 Q4 | 7.58 Million HKD | 0.0% |
| 2008 Q2 | 17.43 Million HKD | 0.0% |
| 2008 Q4 | 1.09 Million HKD | 0.0% |
| 2008 Q3 | 1.09 Million HKD | -93.73% |
| 2008 Q1 | 17.43 Million HKD | 0.0% |
| 2008 FY | -12.04 Million HKD | -117.27% |
| 2007 Q2 | -1.9 Million HKD | 0.0% |
| 2007 Q1 | -1.9 Million HKD | 0.0% |
| 2007 FY | 69.73 Million HKD | 1016.05% |
| 2007 Q4 | 17.43 Million HKD | 0.0% |
| 2007 Q3 | 17.43 Million HKD | 1016.05% |
| 2006 Q3 | -1.9 Million HKD | 84.17% |
| 2006 Q2 | -12.02 Million HKD | 0.0% |
| 2006 Q1 | -12.02 Million HKD | 0.0% |
| 2006 FY | -7.61 Million HKD | 84.17% |
| 2006 Q4 | -1.9 Million HKD | 0.0% |
| 2005 Q3 | -12.02 Million HKD | -3.63% |
| 2005 FY | -48.1 Million HKD | -16.91% |
| 2005 Q1 | -11.6 Million HKD | 0.0% |
| 2005 Q2 | -11.6 Million HKD | 0.0% |
| 2005 Q4 | -12.02 Million HKD | 0.0% |
| 2004 Q4 | -11.6 Million HKD | 0.0% |
| 2004 Q1 | -7.55 Million HKD | 0.0% |
| 2004 FY | -41.14 Million HKD | -47.63% |
| 2004 Q3 | -11.6 Million HKD | -53.54% |
| 2004 Q2 | -7.55 Million HKD | 0.0% |
| 2003 Q3 | -7.55 Million HKD | 0.0% |
| 2003 FY | -27.86 Million HKD | 0.0% |
| 2003 Q4 | -7.55 Million HKD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 143.01 Million HKD | 71.415% |
| Grand Pharmaceutical Group Limited | 2.66 Billion HKD | 98.465% |
| Extrawell Pharmaceutical Holdings Limited | -8.16 Million HKD | 600.858% |
| Qianhai Health Holdings Limited | -52.18 Million HKD | 178.34% |
| Lee's Pharmaceutical Holdings Limited | 36.04 Million HKD | -13.423% |
| Essex Bio-Technology Limited | 310.32 Million HKD | 86.827% |
| Tongfang Kontafarma Holdings Limited | - HKD | -Infinity% |
| PuraPharm Corporation Limited | -66.04 Million HKD | 161.896% |
| SSY Group Limited | 1.63 Billion HKD | 97.506% |
| JBM (Healthcare) Limited | 174.2 Million HKD | 76.533% |
| Jacobson Pharma Corporation Limited | 333.12 Million HKD | 87.728% |
| China Resources Pharmaceutical Group Limited | 12.14 Billion HKD | 99.663% |